SQZ vs. TCBP, SCNI, ACOR, WINT, ACORQ, GMDA, GMDAQ, ELOX, ALBT, and KRBP
Should you be buying SQZ Biotechnologies stock or one of its competitors? The main competitors of SQZ Biotechnologies include TC Biopharm (TCBP), Scinai Immunotherapeutics (SCNI), Acorda Therapeutics (ACOR), Windtree Therapeutics (WINT), Acorda Therapeutics (ACORQ), Gamida Cell (GMDA), Gamida Cell (GMDAQ), Eloxx Pharmaceuticals (ELOX), Avalon GloboCare (ALBT), and Kiromic BioPharma (KRBP). These companies are all part of the "biological products, except diagnostic" industry.
SQZ Biotechnologies (NYSE:SQZ) and TC Biopharm (NASDAQ:TCBP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.
TC Biopharm has a consensus price target of $1,400.00, suggesting a potential upside of 95,138.10%. Given TC Biopharm's higher possible upside, analysts plainly believe TC Biopharm is more favorable than SQZ Biotechnologies.
TC Biopharm has a net margin of 0.00% compared to SQZ Biotechnologies' net margin of -369.96%. TC Biopharm's return on equity of 0.00% beat SQZ Biotechnologies' return on equity.
38.5% of SQZ Biotechnologies shares are held by institutional investors. Comparatively, 16.3% of TC Biopharm shares are held by institutional investors. 16.0% of SQZ Biotechnologies shares are held by company insiders. Comparatively, 0.1% of TC Biopharm shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
TC Biopharm has lower revenue, but higher earnings than SQZ Biotechnologies.
In the previous week, SQZ Biotechnologies had 1 more articles in the media than TC Biopharm. MarketBeat recorded 1 mentions for SQZ Biotechnologies and 0 mentions for TC Biopharm. SQZ Biotechnologies' average media sentiment score of 0.00 equaled TC Biopharm'saverage media sentiment score.
SQZ Biotechnologies has a beta of 2.34, meaning that its stock price is 134% more volatile than the S&P 500. Comparatively, TC Biopharm has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500.
SQZ Biotechnologies received 9 more outperform votes than TC Biopharm when rated by MarketBeat users. Likewise, 66.67% of users gave SQZ Biotechnologies an outperform vote while only 50.00% of users gave TC Biopharm an outperform vote.
Summary
SQZ Biotechnologies beats TC Biopharm on 7 of the 13 factors compared between the two stocks.
Get SQZ Biotechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for SQZ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SQZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SQZ Biotechnologies Competitors List
Related Companies and Tools
